Publication Name	World Journal of Diabetes
Manuscript ID	41697
Country	United States

Received	2018-08-22 03:15
Peer-Review Started	2018-08-22 09:05
To Make the First Decision	2018-10-08 03:37
Return for Revision	2018-10-10 02:23
Revised	2018-10-10 15:57
Second Decision	2018-11-14 11:18
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2018-11-15 17:35
Articles in Press	2018-11-15 17:35
Publication Fee Transferred
Edit the Manuscript by Language Editor	2018-11-24 00:53
Typeset the Manuscript	2018-12-03 03:07
Publish the Manuscript Online	2018-12-14 01:19

ISSN	1948-9358 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Observational Study
Article Title	Using real world data to assess cardiovascular outcomes of two antidiabetic treatment classes
Manuscript Source	Unsolicited Manuscript
All Author List	Manfred Paul Stapff
ORCID	Author(s) ORCID Number Manfred Paul Stapff http://orcid.org/000-0002-6127-1109
Funding Agency and Grant Number
Corresponding Author	Manfred Paul Stapff, MD, PhD, CMO, TriNetX Inc., 125 Cambridgepark Drive, Ste 500, Cambridge, MA 02140, United States. manfred.stapff@trinetx.com
Key Words	Sodium-glucose co-transporter-2 inhibitors; Cardiovascular events; Clinical trials; Electronic medical records; Dipeptidyl peptidase 4 inhibitors; Real world evidence; Diabetes
Core Tip	Core tip: Cardiovascular advantages of sodium-glucose co-transporter-2 (SGLT2) inhibitors were shown in com­plex clinical trials or in countries with large registries. However, it was unclear whether these findings could be applied to routine medical practice in the US. This real world analysis from 46909 patients with SGLT2 inhibitors revealed a 0.63 (95%CI: 0.60-0.66) risk ra­tio of SGLT2 inhibitors compared to 189120 patients with dipeptidyl peptidase 4 inhibitors. This analysis of electronic health records could replicate the results of randomized clinical trials, which supports the usefulness of such real world studies (e.g., for long-term outcome or safety observations).
Publish Date	2018-12-14 01:19
Citation	Stapff MP. Using real world data to assess cardiovascular out­comes of two antidiabetic treatment classes. World J Diabetes 2018; 9(12): 252-257
URL	https://www.wjgnet.com/1948-9358/full/v9/i12/252.htm
DOI	https://dx.doi.org/10.4239/wjd.v9.i12.252

Full Article (PDF)	WJD-9-252.pdf
Full Article (Word)	WJD-9-252.doc
STROBE Statement	41697-STROBE Statement.pdf
Manuscript File	41697-Review.docx
Answering Reviewers	41697-Answering reviewers.pdf
Audio Core Tip	41697-Audio core tip.mp3
Biostatistics Review Certificate	41697-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	41697-Conflict-of-interest statement.pdf
Copyright License Agreement	41697-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s)	41697-Informed consent statement.pdf
Institutional Review Board Approval Form or Document	41697-Institutional review board statement.pdf
Peer-review Report	41697-Peer-review(s).pdf
Scientific Misconduct Check	41697-Scientific misconduct check.pdf
Scientific Editor Work List	41697-Scientific editor work list.pdf